Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H31N5O4 |
Molecular Weight | 429.5126 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(O)=O)C3CCCCC3)C=C1
InChI
InChIKey=DKWNMCUOEDMMIN-PKOBYXMFSA-N
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
Molecular Formula | C22H31N5O4 |
Molecular Weight | 429.5126 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:30:52 UTC 2023
by
admin
on
Fri Dec 15 16:30:52 UTC 2023
|
Record UNII |
2A9QP32MD4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B01AE04
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
||
|
WHO-VATC |
QB01AE04
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB13616
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
m7149
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
43966
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
159776-70-2
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
C66077
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
DTXSID30166724
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
100000081464
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
CHEMBL266349
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
7414
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
C109573
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
SUB08718MIG
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
2A9QP32MD4
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY | |||
|
183797
Created by
admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
Of the human subjects, one male and one female had essentially no plasma protein binding of melagatran, whereas the other two had values of 13.3 and 15.3%.
BINDING
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||